Please assess the completion status of the following clinical trial:

Trial Title: Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed unresectable metastatic melanoma~  * Must have asymptomatic brain metastasis that is not amenable to surgery or stereotactic radiosurgery (gamma knife, Linac)~ * Must have concurrent visceral/soft tissue metastases~* At least 1 site of measurable disease (not necessarily the brain metastasis)~* Documented evidence of disease progression defined by 1 of the following conditions:~  * More than 25% increase in the size of at least 1 measurable lesion~ * Appearance of a new lesion~ * A significant increase in the size of nonmeasurable disease~* No neurological symptoms, including signs of elevated intracranial pressure~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 10 g/dL~Hepatic:~* Bilirubin less than 1.5 times upper limit of normal (ULN)~* SGOT or SGPT less than 3 times ULN~* Alkaline phosphatase less than 3 times ULN~Renal:~* Urea less than 1.5 times ULN~* Creatinine less than 1.5 times ULN~Other:~* No frequent vomiting or medical condition (e.g., partial bowel obstruction) that would interfere with oral medication intake~* No other prior or concurrent malignancy except surgically cured carcinoma in situ of the cervix or basal cell or squamous cell skin cancer~* No uncontrolled infection~* HIV negative~* No AIDS-related illness~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No psychological, familial, sociological, or geographical condition that would preclude study~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Prior cytokine via isolated limb perfusion for local-regional melanoma allowed~* No other prior cytokine for metastatic melanoma~* No concurrent colony-stimulating factors, including epoetin alfa or filgrastim (G-CSF)~* No other concurrent immunologic or biologic therapy~Chemotherapy:~* Prior chemotherapy via isolated limb perfusion for local-regional melanoma allowed~* No other prior chemotherapy for metastatic melanoma~* No other concurrent chemotherapy~Endocrine therapy:~* Concurrent corticosteroids allowed during radiotherapy (arm II only)~* No concurrent hormonal therapy~Radiotherapy:~* See Disease Characteristics~* No other concurrent radiotherapy~Surgery:~* See Disease Characteristics~* Recovered from the effects of any prior major surgery~Other:~* No other concurrent investigational drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues